About
Adrian Adams has served as a member of Akebia Therapeutics' Board of Directors since the completion of the merger with Keryx Biopharmaceuticals, Inc. in December 2018, and serves as Chairperson of the Board. He has more than 30 years of experience in the pharmaceutical and biotechnology industries, including numerous roles as Chief Executive Officer. From January 2020 to November 2023 he was Chief Executive Officer and Chairman of the board of Impel Pharmaceuticals, Inc., and from 2016 to 2019 he was Chief Executive Officer and a director of Aralez Pharmaceuticals Inc. He has previously led Auxilium Pharmaceuticals, POZEN, Kos Pharmaceuticals, Sepracor, Inspire Pharmaceuticals and Neurologix, and held senior positions at Novartis, SmithKline Beecham and Imperial Chemical Industries.
Roles
Akebia Therapeutics, Inc.
Director (Class III), Chairperson · Current role
2018–present
Impel Pharmaceuticals, Inc.
Chief Executive Officer and Chairman of the board · Public biotechnology company.
2020-2023
Aralez Pharmaceuticals Inc.
Chief Executive Officer and director · Pharmaceutical company focused on cardiovascular, pain and other therapies.
2016-2019
POZEN, Inc.
Chief Executive Officer and director · Combined with Tribute Pharmaceuticals Canada to become Aralez Pharmaceuticals in 2016.
2015-2016
Auxilium Pharmaceuticals, Inc.
Chief Executive Officer, President and director · Specialty biopharmaceutical company; acquired by Endo International plc in 2015.
2011-2015
External Roles
Talphera, Inc.
Chairman of the board of directors
—
Director Compensation
FY 2025
Fees earned or paid in cash
$92,500
Also at Akebia Therapeutics, Inc.